Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 15/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | GFER | P55789 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.73 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.59 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.59 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | ESRRB | O95718 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | ESRRG | P62508 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8271091 | 1.00 | ESRRA (1.00) | ESRRAMAPTMCL1NPSR1MEN1 | |
| SCHEMBL5507657 | 1.00 | ESRRA (1.00) | ESRRAMAPTMCL1NPSR1MEN1 | |
| SCHEMBL5505359 | 0.88 | ESRRA (0.78) | ESRRAMAPTMCL1NPSR1MEN1 | |
| SCHEMBL8271633 | 0.88 | ESRRA (0.78) | ESRRAMAPTMCL1NPSR1MEN1 | |
| SCHEMBL5505362 | 0.88 | ESRRA (0.78) | ESRRAMAPTMCL1NPSR1MEN1 | |
| SCHEMBL5504421 | 0.87 | ESRRA (0.77) | ESRRAMAPTMCL1NPSR1MEN1 | |
| SCHEMBL5504425 | 0.87 | ESRRA (0.77) | ESRRAMAPTMCL1NPSR1MEN1 | |
| SCHEMBL2383143 | 0.84 | ESRRA (1.00) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL2383139 | 0.84 | ESRRA (1.00) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL8170341 | 0.84 | ESRRA (1.00) | ESRRACYP3A4PIM1PDE4BPIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781271-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-09 | — | — | EP | claimed |
| WO-2006019741-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | WO | claimed |
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-19 | — | — | US | claimed |
| EP-1781271-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006019741-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | ESR2, ESRRG, GPER1 | ESRRA 5/4885MAPT 4442/4885MCL1 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.